Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular dystrophies like FSHD and myotonic dystrophy, using strategies to knock down ...

New research has demonstrated that a combined regimen of growth hormone and testosterone is safe, well-tolerated, and is associated with meaningful improvements in muscle mass, strength, and mobility ...

Disease-foundation-funded program extends NovMetaPharma’s muscle-preservation platform into a serious neuromuscular disease with no approved disease-modifying treatment; collaboration provides ...

Please provide your email address to receive an email when new articles are posted on . Treatment with losmapimod and placebo had similar results with respect to primary, secondary endpoints. No ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for ...

A recent study has found that the SMCHD1 protein plays a key role in controlling how genes are processed, which affects the progression of Facioscapulohumeral Muscular Dystrophy (FSHD). This discovery ...

Please provide your email address to receive an email when new articles are posted on . Safety and tolerability of losmapimod were assessed in 108 people with facioscapulohumeral muscular dystrophy.

Armed with $68 million in Series B funding, Epicrispr Biotechnologies (Epic) is initiating human trials of its lead candidate EPI-321, an epigenetic therapy for the neuromuscular disorder, ...

Researchers at Kumamoto University have demonstrated that iron supplementation can significantly alleviate muscle pathology and functional decline in a mouse model of facioscapulohumeral muscular ...

CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically ...

- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root cause ...